Introduction
============

Worldwide, cervical cancer accounts for an estimated 528,000 new cancer cases and 266,000 deaths each year \[[@ref1]\]. In under-developed regions, cervical cancer is the second most common type of cancer as well as the third most common cause of cancer related deaths \[[@ref2]\]. However, in developed countries with increased screening across the population, cervical cancer represents the 11th most common type of cancer and ninth most common cause of cancer related mortality \[[@ref3]\]. The American Cancer society estimates about 13,240 new cases of cervical cancer will be diagnosed in the United States in 2018, with approximately 4,170 deaths from the disease \[[@ref4]\]. Pelvic organ prolapse is a far more common disease, estimated to occur in roughly 40%--60% of parous women \[[@ref5]\]. The association between cervical cancer and uterovaginal prolapse is an exceedingly rare occurrence in developed countries. There has been minimal literature reported with no current guidelines in regards to the treatment. This is a case-report of cervical carcinoma with invasion of stage IV uterine prolapse and lung metastasis with a full systematic review of the current literature on management patterns and outcomes. This is the first reported case of PD-L1 cervical cancer with invasion of uterovaginal prolapse as well as the first reported case undergoing immunotherapy. Additionally, this is the first complete systematic review performed investigating past cases of cervical cancer associated with pelvic organ prolapse.

Case report
===========

This is a 68 year-old post-menopausal, gravida four para three, with a long standing history of uterovaginal prolapse. The patient was unable to describe the duration of her procidentia but reported that the prolapse began to protrude past the vagina for seven months prior to presentation and has been unable to reduce the mass. The patient then began to note a large malodorous, fungating lesion on the prolapse associated with vaginal bleeding. At time of presentation, physical exam revealed a 14 cm × 10 cm necrotic mass ([Figure 1](#figure1){ref-type="fig"}).

A biopsy of the lesion was preformed establishing the diagnosis of invasive squamous cell carcinoma, moderately to poorly differentiated, focally keratinising with a background of high-grade intraepithelial lesion. Computed tomography (CT) of the abdomen and pelvis demonstrated prolapse of part of the bladder, entire uterus and vagina with the gonadal vessels extending inferior to the perineum with two noncalcified lung nodules (8 mm right middle lobe, 5 mm left lower lobe). Follow-up positron emission tomography/computed tomography (PET/CT) showed severe anterior, middle and posterior compartment prolapse with protruded mass with peripheral FDG uptake ([Figure 2](#figure2){ref-type="fig"}); hypermetabolic left common iliac, external iliac and obturator lymphadenopathy, few with mild FDG uptake, and mildly FDG avid hilar lymph nodes that are likely reactive.

The patient was diagnosed with stage IIB invasive squamous cell carcinoma of the cervix. Given the finding of PET positive pelvic lymph nodes---along with the size of the tumour---she was not a surgical candidate. The patient underwent four total cycles of weekly Cisplatin 40 mg/m^2^ with 16 fractions of pelvic extended field radiation therapy. The evaluation on each office visit demonstrated areas of resolving necrosis with improvement on each subsequent exam. A follow-up PET/CT 2 months after the completion of therapy demonstrated a decrease in degree of hypermetabolic activity associated with cervical mass hypermetabolic pelvic lymphadenopathy with a new 2.7 cm markedly hypermetabolic right upper lobe nodule suspicious for new metastasis. The patient underwent CT-guided fine-needle aspiration biopsy of the right pulmonary nodule. Pathology demonstrated squamous cell carcinoma, likely metastatic. Immunohistochemistry was p40 positive and strongly p16 positive in support of metastatic disease, HPV was negative. Further testing demonstrated positive PD-L1 and received four cycles of pembrolizumab 200 mg. She also began experiencing worsening, persistent lower back pain. MRI of the lumbar spine demonstrated left lumbar vertebral metastasis. The patient died of disease 12 months following diagnosis.

Method
======

This study was registered with PROSPERO, the international prospective register of systematic reviews and followed the guidelines set forth by the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement.\[[@ref6]\] A comprehensive literature search was conducted using the following bibliographic databases: Ovid MEDLINE® (In-Process & Other Non-Indexed Citations and Ovid MEDLINE® 1946 to Present), Ovid EMBASE (1974 to present), and The Cochrane Library (Wiley). There were no language, date, or article type restrictions included in the search.

Strategy for search of articles and selection criteria
------------------------------------------------------

This study was registered with PROSPERO, the international prospective register of systematic reviews and followed the guidelines set forth by the PRISMA statement \[[@ref6]\]. A comprehensive literature search was conducted by the institutional medical librarian team on January 11, 2018 using the following bibliographic databases from inception: Ovid MEDLINE® (In-Process & Other Non-Indexed Citations and Ovid MEDLINE® 1946 to Present), Ovid EMBASE (1974 to present), and The Cochrane Library (Wiley). No language, publication date or article type restrictions were included in the search.

Data for the number of patients with cervical cancer with pathology confirmed invasion of uterovaginal prolapse was extracted from each study. Additionally, data on age, race, body mass index, family history criteria, tumour stage, tumour grade and histologic type were obtained where available. Data were entered into and exported from the Covidence online software program. Two independent investigators retrieved the data.

Study proportions were pooled and. Patient characteristics (i.e., age, tumour grade, histology, management and outcomes) were averaged over the studies to provide descriptive information. Publication bias was not assessed in this systematic review. All analyses were performed with the use of GraphPad Prism statistical software (Version 8.2.0)

Results
=======

Discussion
==========

Tumour invasion of prolapsed uterine corpus is uncommon among cervical cancer cases. Given the lack of reported cases and minimal literature on the topic, uterine corpus tumour invasion is not yet considered as a surgical-pathological risk factor, nor is it considered as a reliable marker for prognosis for women with cervical cancer \[[@ref7]\]. A 2017 study by Matsuo *et al* \[[@ref7]\] investigated 30 years of national data and identified 837 (4.9%) cases of uterine invasion among 17,074 cases of early-stage cervical cancer who underwent hysterectomy, however, none exhibited invasion of pelvic organ prolapse. This study demonstrated that invasion is typically associated with older age, non-squamous histology, high-grade tumours, larger tumour size and node status. Additionally, invasion was associated with a significant decrease in cause-specific survival when compared to cases without invasion \[[@ref7]\]. Given decreased survival outcome among cervical cancer patients with tumour extension to adjacent organs, this study ultimately shows that uterine corpus invasion likely reflects aggressive tumour behaviour.

Cervical cancer invasion of complete uterovginal prolapse is exceedingly rare in developed countries. One of the first reported cases was in 1958 (Rocker *et al*), followed by reports in 1963 (Cabaniss *et al*) and 1972 (Daw *et al*) We performed a systematic review of PubMed, Embase, Medline and the Cochrane Library. A total of 13 reported cases of cancer association with uterovaginal prolapse were identified between 1990 and 2017. Reports ranged from different countries around the world including Austria, Brazil (two cases), France, Germany, India, Italy, Morocco, Portugal, Spain, Taiwan, Turkey and the United States. [Table 1](#table1){ref-type="table"} lists each study with comparison of characteristics, management and outcomes \[[@ref8]--[@ref21]\].

The mean age at diagnosis among the reports is 74.4, ranging from 54 to 89 years of age. 13 of the 14 cases were squamous cell carcinoma of the cervix, one with verrucous features and one reported case of clear cell adenocarcinoma. Two cases presented with Stage I (14.2%), nine with Stage II (64.2%), three with Stage III (21.4%) and none with Stage IV. All had complete uterovaginal prolapse. Two cases did not undergo surgery (both stage IIIB), the third reported case of stage IIIB in Pardal *et al* \[[@ref17]\] underwent total vaginal hysterectomy and partial colpectomy with colpoclesis. Eight cases underwent vaginal hysterectomy (57.1%), one underwent laparoscopic radical hysterectomy (7.1%). Three cases underwent lymphadenectomy (21.4%). Five surgeries addressed the pelvic organ prolapse (35.7%); one case performed perineorrhaphy, cystocele, enterocele and Gellhorn pessary placement, one case with intraabdominal uterosacral ligament suspension, and colpoclesis performed in three. Three cases did not receive chemotherapy or radiation. Ten cases received pelvic radiotherapy (71.4%), four received a combination of chemoradiation (28.5%)--- all with cisplatin and one with 5-fluorouracil plus cisplatin. Patient outcomes were mixed. Seven patients were free of disease throughout follow-up (mean 21.5 months, ranging 6--60 months of follow-up reported). There were three deaths reported, two from disease (14.2%) at 3 and 12 months, and one from pulmonary embolism 20 days following surgery. Three cases did not report on the outcome and one case was last to follow up at 2 months.

Currently, there is no evidence-based management for cervical cancer associated with uterovaginal prolapse. Most reported cases in the literature suggest a radical vaginal hysterectomy with bilateral iliopelvic lymphadenectomy, external pelvic radiation and chemotherapy \[[@ref17]\]. The decision for management must consider staging, the extent of spread, degree of procidentia and cystocele-rectocele involvement with risk of visceral injury following radiotherapy. The patient described above underwent PD-L1 testing with an attempt at alternative immunotherapy in hopes to optimise treatment. In June, 2018, the Food and Drug Administration approved pembrolizumab (Keytruda) with advanced, PD-L1-positive cervical cancer with progression while on or following chemotherapy. This decision was based on data from the Phase II KEYNOTE-158 trial which demonstrated an overall response rate of 17% (27% among patients with ≥27 weeks of follow-up) in advanced cervical squamous cell carcinomas \[[@ref22]\]. This case further demonstrates the need for more literature surrounding cervical cancer with uterine invasion, especially associated with pelvic organ prolapse, in order to determine the most effective therapies.

Conclusion
==========

Overall, cervical cancer with invasion of uterovaginal prolapse is exceedingly rare in developed countries. There have been a total of 13 reported cases in the literature of cervical cancer association with uterovaginal prolapse between 1990 and 2017, each with various treatments and outcomes. There are no current management guidelines for cervical cancer with invasion of pelvic organ prolapse. As demonstrated from this study, management varies widely across the literature. However, a majority of cases underwent vaginal hysterectomy (57.1%) and pelvic radiotherapy (71.4%). The case reported above demonstrates the need to pursue additional biomarkers and therapies among this rare population. Especially, given the recent approval of pembrolizumab for advanced, PD-L1-positive cervical cancer with progression while on or following chemotherapy, PD-L1 testing and immunotherapy options should be considered. Further studies are necessary to further identify effective treatment strategies of uterovaginal prolapse associated with carcinoma of the cervix.
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![Image of 14 cm × 10 cm necrotic mass associated with stage 4 uterine prolapse on presentation.](can-14-1043fig1){#figure1}

![PET/CT demonstrating severe anterior, middle, and posterior compartment prolapse, with protruded mass with peripheral FDG uptake.](can-14-1043fig2){#figure2}

###### Systematic review data of published cases of carcinoma of the cervix associated with procidentia.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                             Age   Histology                             Stage   Surgery                                                                                                                                                  Chemotherapy/Radiotherapy                                                                                                                                                                                                                      Outcome
  ---------------------------------- ----- ------------------------------------- ------- -------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Borgas de Silva 2001 \[[@ref8]\]   69    Squamous cell carcinoma               IIA     Radical vaginal hysterectomy with bilateral salpingoo-ophorectomy and vaginal, parametrial resection                                                     External pelvic radiotherapy at a total dose of 5,000 cGy fractionated over a period of 5 weeks                                                                                                                                                Free of disease at 2 years, lost to follow-up since

  Borgas de Silva 2001               73    Squamous cell carcinoma               IIA     Radical vaginal hysterectomy                                                                                                                             External pelvic radiotherapy at a total dose of 5,000 cGy fractionated over a period of 5 weeks                                                                                                                                                Alive with no signs of recurrence 2 years after surgery

  Cabrera 2010 \[[@ref9]\]           54    Clear cell adenocarcinoma             IB2     Laparoscopic radical hysterectomy with bilateral salpingo-oophorectomy, pelvic lymphadenectomy and para-aortic lymph node sampling                       Adjuvant chemoradiotherapy, 46 Gy. Chemotherapy based\                                                                                                                                                                                         Alive with no signs of relapse 10 months after treatment
                                                                                                                                                                                                                                                  on 5-fluorouracil plus cisplatin                                                                                                                                                                                                               

  Cheung 2012 \[[@ref10]\]           77    Squamous cell carcinoma               IIB     Total excision                                                                                                                                           Post-operative tomoradiation of 6,000 cGy in 30 fractions to the pelvis                                                                                                                                                                        Not reported

  Chung 2018 \[[@ref11]\]            67    Squamous cell carcinoma               IIA2    Total vaginal hysterectomy, exploratory laparotomy, bilateral Salpingooophorectomy, cancer staging, and intraabdominal uterosacral ligament suspension   Adjuvant chemoradiation                                                                                                                                                                                                                        Not reported

  Dane 2009 \[[@ref12]\]             89    Squamous cell carcinoma (Verrucous)   IIA     Resection of the vagina and parametria                                                                                                                   Did not receive                                                                                                                                                                                                                                Free of disease at 6 months of follow up

  Dawkins 2018 \[[@ref13]\]          72    Squamous cell carcinoma               IIA2    Perineorrhaphy, cystocele, enterocele repair, Gellhorn pessary placement                                                                                 External beam radiation therapy, vaginal brachytherapy. Chemotherapy with cisplatin                                                                                                                                                            Free of disease at 15 months

  El-Abbassi 2017 \[[@ref14]\]       79    Squamous cell carcinoma               IIIB    Did not undergo surgery                                                                                                                                  Palliative Chemotherapy                                                                                                                                                                                                                        Dead of Disease at 3 months

  Kriplani 1995 \[[@ref15]\]         60    Squamous cell carcinoma               IIIB    Did not undergo surgery                                                                                                                                  Radiotherapy for a total of 50 Grays, 27 fractions over 5.5 weeks                                                                                                                                                                              Subsequent visit 2 months after completion of radiotherapy did not reveal any disease. Intracavitary radiotherapy was planned but the patient did not return for follow-up

  Loizzi 2010 \[[@ref16]\]           86    Squamous cell carcinoma               IIA     Vaginal hysterectomy with upper vaginectomy in spinal anesthesia due to poor performance status                                                          Did not receive                                                                                                                                                                                                                                Died of pulmonary embolism 20 days after surgery

  Pardal 2015 \[[@ref17]\]           74    Squamous cell carcinoma               IIIB    Vaginal hysterectomy plus open bilateral iliopelvic lymphadenectomy                                                                                      Pelvic external beam radiotherapy 50Gy/25F plus vaginal brachytherapy 3×7Gy) and chemotherapy with cisplatin (40 mg/m^2^/weekly). Disease progressed, palliative therapy with paclitaxel (175 mg/m^2^) plus carboplatin (AUC5) every 3weeks.   Twelve months after the diagnosis the patient was admitted in the hospital due to an insidious onset of altered mental status and end-life care performed

  Reimer 2008 \[[@ref18]\]           73    Squamous cell carcinoma               IIA     Total vaginal hysterectomy and partial colpectomy with colpocleisis                                                                                      Combined pelvic radiotherapy with cisplatin                                                                                                                                                                                                    After five years of follow up, no disease recurrent and pelvic floor stability

  Reisenauer 2017 \[[@ref19]\]       81    Squamous cell carcinoma               IIA     Vaginal radical hysterectomy, salpingo-oophorectomy, laparoscopic sentinel pelvic lymphadenectomy, Le Fort colpoclesis                                   Did not receive                                                                                                                                                                                                                                Not reported

  Vieillefosse 2014 \[[@ref20]\]     87    Squamous cell carcinoma               IB2     Rouhier proceure: Modified LeFort colopcleisis with hysterectomy                                                                                         External pelvic radiotherapy (dosing not reported)                                                                                                                                                                                             Free of disease at 1 year

  Cabanis 1963 \[[@ref21]\]          68    Squamous cell carcinoma               IIB     \-\--                                                                                                                                                    \-\--                                                                                                                                                                                                                                          Alive with disease at 8 months, lung metastasis
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
